Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 5Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Targeted Therapy 1Spinal Cord Neoplasms 1Oligodendroglioma 1Myeloproliferative Disorders 1Myeloid Malignancies 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 7Radiotherapy 3Everolimus 3nimotuzumab 2Erlotinib Hydrochloride 2Cyclophosphamide 2Bevacizumab 2tovorafenib 1ribociclib 1palbociclib 1olutasidenib 1antineoplaston AS 2-1 1antineoplaston A10 1Vinorelbine 1Valproic Acid 1Topotecan 1TIC10 compound 1Radiation 1Proto-Oncogene Proteins c-akt 1Phosphatidylinositol 3-Kinases 1Panobinostat 1Lomustine 1Irinotecan 1Injections 1GDC-0084 1Etoposide 1Drug Therapy 1Doxorubicin 1Diphtheria-Tetanus Vaccine 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Diffuse Intrinsic Pontine Glioma × olutasidenib × Clear all
NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Rigel Pharmaceuticals

Phase 2 Recruiting
60 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡